OBR Daily Commentary

forumImage

Imfinzi Significantly Reduces The Risk Of Disease Worsening Or Death in the Phase III PACIFIC Trial for Stage III Unresectable Lung Cancer

(AstraZeneca) May 12, 2017 - Imfinzi met a primary endpoint of statistically-significant and clinically-meaningful progression-free survival (PFS) in ‘all-comer’ patients with locally-advanced, unresectable (Stage III) non-small cell lung cancer in a planned interim analysis; Imfinzi is the first immuno-oncology medicine to show superior PFS in this setting; plans for regulatory submission under active discussion with authorities.

Read Article arrow

H. Jack West, MD (Posted: May 12, 2017)

quotesThough it will be far more important to see this difference translate to a significant improvement in overall survival, this early result based on an interim report is very encouraging and has great potential to finally improve on our longstanding standard of concurrent chemo/radiation in patients with locally advanced NSCLC. Along with needing to clarify whether there is an overall survival advantage, we will need to clarify whether the benefits of durvalumab are seen comparably in patients with squamous and non-squamous NSCLC and across different levels of PD-L1 expression. These results will be among the most anticipated in lung cancer over the next several months.quotes

Reply

Add Comment 1 Comment(s)

Meet the Editorial Board

Community Oncology
member photo
Dean Gesme, MD

FACP FACPE FASCO President, Minnesota Oncology...

Breast Cancer
member photo
Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncol...

Lung Cancer
member photo
H. Jack West, MD

Medical Director, Thoracic Oncology Program, Swedish Ca...

Gastrointestinal Cancers
member photo
Howard S. Hochster, MD

Associate Cancer Center Director, Yale Cancer Center P...

Community Oncology
member photo
Jeff Patton, M.D.

CEO Tennessee Oncology...

Precision Medicine Section Editor
member photo
Jennifer Levin Carter, MD, MPH

Chief Medical Officer and Founder, N-of-One...

Financial Sector
member photo
Michael G. King Jr.

Managing Director and Senior Biotechnology Analyst...

Gastrointestinal Cancers
member photo
Richard Goldberg, MD

Director WVU Cancer Institute Director of Cancer Signa...

Editor-In-Chief
member photo
Robert A. Figlin, MD., FACP

Professor and Director, Division of Hematology Oncology...

Health Policy
member photo
Ted Okon

Executive Director Community Oncology Alliance...

Community Oncology
member photo
Thomas Marsland, MD

Vice President Integrated Community Oncology Network ...

Community Oncology
member photo
William Harwin MD

Florida Cancer Specialists President and Managing Part...

Health Policy
member photo
William McGivney, PhD

National Health Policy Expert...

Payer
member photo
Winston Wong, PharmD

President, W-Squared Group...